Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OTLK - The pre-offer of a Buyout has started? (More opinions I read regarding a OTLK Buyout)
"I Think the pre-offer buying of OTLK Buyout has started!"
A buyout will be based on the value to the buyer, not the share price.
A low share price means a potential buyer may try to buy up as many shares pre-offer as possible.
Let's say you offer $30/share.
If you accumulated 10MM shares before the offer was made, you saved $300MM dollars.
If someone beats your offer, you still sell those 10MM shares for a profit.
I think this is why we are seeing bear raids and FUD accounts.
I think the pre-offer buying has started.
I expect an offer to be announced around the time the FDA accepts the BLA.
Any offer will be based on the buyer's valuation.
Whoever has the highest valuation will make the highest offer.
Share price won't matter a lick.
So a $30/share offer is reasonable, if a buyer thinks the value is there.
This is why I keep saying that none of us has enough information to know what the offer will be.
But I think it will be $8-$12MMM . Or less. Probably not more. I would be amazed if it's less than $5MMM
For more information about OTLK, see at r/OTLK_Investors
$OTLK JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th
PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022. As part of the virtual event, JTC partnered companies will provide a corporate presentation, followed by an interactive Q&A session.
The schedule for the event is as follows:
Tuesday, January 25, 2022
3:00 PM ET: Outlook Therapeutics, Inc. (Nasdaq:OTLK) - WEBCAST
- Access the event and schedule of presenting companies at virtualinvestorco.com -
- Live video webcast presentations of participating companies followed by interactive Q&A session -
Its working.
I copy r/OTLK_Investors to google and works.
OTLK - Corporate Presentation January 2022
Good news, ...everything is progressing as planned.
For more information about OTLK see at r/OTLK_Investors
Source:
https://ir.outlooktherapeutics.com/static-files/8a3fe36f-d7e7-4453-806b-2ffbfeb502c3
If you want to see more information about OTLK and also about a potential Buyout, take a look at r/OTLK_Investors
Very good posts there.
OTLK - Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress
Suber Huang, MD, MBA, FASRS will present data from the Phase 3 pivotal NORSE TWO registration trial
ISELIN, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Suber Huang, MD, MBA, FASRS, Founder and CEO of the Retina Center of Ohio, will present safety and efficacy data from Outlook Therapeutics’ Phase 3 pivotal
NORSE TWO trial evaluating ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab, for use in wet AMD.
The presentation will take place virtually at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress on December 10, 2021 at 11:20 – 11:30 PM ET (December 11, 2021 at 12:20 – 12:30 PM HKT).
“It is exciting to see the success of the NORSE TWO trial,” said Dr. Huang. “The clinical results from NORSE TWO were highly significant and move Outlook Therapeutics one step closer towards providing patients and retina specialists with the first on-label ophthalmic bevacizumab. If approved, ONS-5010 will avoid the potentially serious adverse events associated with off-label repackaged IV bevacizumab from compounding pharmacies.”
Details for the special plenary session presentation are as follows:
Safety and Efficacy Results of ONS-5010 – An Ophthalmic Bevacizumab from a Phase 3 Study of Monthly Intravitreal ONS-5010 in Subjects with Wet AMD (NORSE TWO)
Presenter: Suber S. Huang, MD, MBA, FASRS
Session: Plenary Session, 0087
Date and time: Friday, December 10, 2021, 11:20 – 11:30 PM ET (Saturday, December 11, 2021, 12:20 – 12:30 PM HKT)
For more information about OTLK see at r/OTLK_Investors
OTLK - Corporate Presentation DECEMBER 2021 with Good News
https://ir.outlooktherapeutics.com/static-files/70539207-f829-4485-a2ba-6242ea3dbb28
On December 06, 2021 OTLK report more 3 Insiders Buy of Common Stock
TRENARY C RUSSELL III (CEO and President) BOUGHT more 25000 units OTLK shares at $1,39 after this transaction he owns a total of 35,000 shares.
EVANSON JEFF (Chief Commercial Officer) BOUGHT more 35200 units OTLK shares at $1.34 after this transaction he owns a total of 1,177,130 shares.
DAGNON TERRY (Chief Operating Officer) BOUGHT more 25201 units OTLK shares at $1,38 after this transaction he owns a total of 1,163,058 shares.
Sources:
https://ir.outlooktherapeutics.com/static-files/3cb4fe50-ba50-4592-bd9c-0af8e56b8430
https://ir.outlooktherapeutics.com/static-files/97bc9453-7243-4848-b9b5-e604ab0fe8bd
https://ir.outlooktherapeutics.com/static-files/3a4a9e4a-9f3b-4ea0-903c-72924e2b2413
OTLK Price Target now is $7 to $8
Buyout will be always above price Target.
Never less then $15.
Later Buyout Higer the Price.
I belive in a Buyout 2022/2023 and can be above $25
$OTLK BUYOUT PROCESS STARTED?:
“BioLexis Pte. Ltd. Owner (GMS Ventures) go to purchase $20 million of OTLK shares to increase their position in OTLK
GMS/BioLexis.
They are doing the same Buyout Strategy that PFIZER did in the TRIL Buyout:
BioLexis owner GMS Ventures, go to increase their investment in OTLK. they will go to Buy more 20 million shares "NOW" and then during the BLA approval process they can launch the Buyout at the time that suits them best.
BioLexis Pte. Limited (BioLexis), the Company’s strategic business partner and largest investor in OTLK.
GMS will make this HUGE investment buying 20 Million Shares because they "KNOW" very well that investment it will be VERY PROFITABLE!
Now OTLK has enough money to finish BLA approval with the Public Offer of $50 Million.
This is one of my vision for OTLK
( See more information about OTLK at r/OTLK_Investors )
OTLK an Excellent Opinion about the Loan.
OTLK >> A very important clue regarding what is happening.
We knew the company was running out of cash.
We also know that they have a large amount of shelf shares still available.
So why would they take out a non-dilutive loan that carries an interest rate instead of selling the shelf?
The only logical reason would be to preserve current share structure.
I cannot believe for one second that they would do this simply to keep current shareholders happy.
If I were to guess it is because there is a negotiated deal for a buyout based on current share structure.
Speculation, but can anyone think of another reason why they would take that loan instead of selling their shelf?
See more info about OTLK at r/OTLK_Investors
(I saw this opinion on the net)
$OTLK PRICE TARGETS and RECOMMENDATIONS on November 04, 2021
PRICE TARGETS/ RECOMMENDATIONS ; Nº of ANALYSTS ESTIMATES
PRICE TARGETS: High $8,40 / Average $7,14 / Low $6,06 :
("CHARTMILL": STRONG BUY-3 Analysts Rating)
PRICE TARGETS: High $8,00 / Average $7,00 / Low $6,00 :
("BARCHART": STRONG BUY-2 Analysts Rating)
("WSJ": BUY-3 Analysts Rating)
("NASDAQ": STRONG BUY-2 Analysts Rating)
("TIP RANKS": MODERATE BUT-2 Aalysts Rating)
("CNN BUSINESS": BUY-3 Aalysts Rating)
("MARKETWATCH": BUY-3 Analysts Rating)
("WALLSTREETZEN": STRONG BUY-2 Analysts Rating)
("WEBULL": BUY-3 Analysts Rating)
("MARKETSCREEN": BUY-3 Analysts Rating)
("BARRONS": BUY-3 Analysts Rating)
("STOCKTARGETADVISOR": BUY-3 Analysts Rating)
See more information about OTLK on r/OTLK_Investors
ONS-5010 (bevacizumab-vikg), for treatment of wet AMD, 12 years market exclusivity under new BLA.
FDA has taken hundreds of unapproved prescription drugs off the market since 2006 and has executed multiple class actions announced through Federal Register Notices.
FDA does not remove an unapproved drug used to treat serious medical conditions until a sufficient and reliable supply of FDA approved drug is available.
FDA Actions to Remove Unapproved Drugs from the Market by Company
https://www.fda.gov/drugs/enforcement-activities-fda/fda-actions-remove-unapproved-drugs-market-company
On OTLK September 2021 Corporate Presentation (Page 15), Seems once it’s FDA approved it will be illegal for pharmacists to compound it off label.
Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
ISELIN, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company?working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab?for use in retinal?indications, today announced that C. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat during the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13 – 15, 2021.
In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, September 13, 2021 at 7:00 AM ET for those registered for the event and accessible on the Events page in the Investors section of the Outlook Therapeutics website (outlooktherapeutics.com) for 90 days.
https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-present-hc-wainwright-23rd-annual-global
OTLK - Corporate Presentation - September 2021 with very good news
https://ir.outlooktherapeutics.com/static-files/9844808b-f00c-49f6-8606-8d1ea9bbf2f2
August 31, 2021 ; OTLK is still have a continues Uptrend since 9 Trading days
On Tuesday August 31, 2021 OTLK have another day with good volume.
Today above 2M, volume was 2.172.300 shares.
OTLK continue with a BUY pressure by Institutional who are buy more shares and also NEW Institutional start buying OTLK Shares.
OTLK with higher highs and higher lows in this upward trend.
OTLK are in a continues Uptrend since 9 trading days (from August 19, 2021 +30,2%).
Buy and STRONG HOLD, for Bid Profits
I believe September will be a great month for OTLK, ...with a great Uptrend.
We are at the end of the month. Let's squeeze the shorts at $OTLK!
$TRIL Today Great news for $TRIL with the Buyout of Pfizer at $18,50. Big Profits.
I started buying TRIL at $0.285 August 22, 2019 and sold it in November 2020 at $20 in November 30, 2020.
Now is the time to think carefully about where to reinvest profits.
I strongly recommend that before investing, you can see OTLK you can see a lot of information about $OTLK at r/OTLK_Investors
My estimate for OTLK is that after BLA approval and start sales reach $25, with the possibility of a Buyout above $50
I reinvested my TRIL Profits on $OTLK (see r/OTLK Investors).
Same details about OTLK Wet AMD
Phase 3 have Great Results and safety.
U.S. FDA BLA submission targeted Q1-2022
BLA Approval 2Q-2022
Pre-commercialization activities underway .
Targeting $13.1 billion global ophthalmic anti-VEGF market.
12 years market exclusivity.
A Buyout to OTLK can happen anytime.
See also the OTLK Corporate Presentation
https://ir.outlooktherapeutics.com/static-files/046a3f66-c668-4bc3-a7c1-916236655b42
OTLK - FORM 10-Q Sec Filling For the quarterly period ended June 30, 2021
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021
https://ir.outlooktherapeutics.com/static-files/ab338a3d-dd0e-43a6-bcdb-2613aa09432a
OTLK - Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update.
RESULTS:
3 Months ended June 30: 2021
Consensus EPS Forecast $(0.08) ; Real (0.07)
("BETTER" Results Than Consensus Forecast)
CORPORATE UPDATE:
Reported positive, statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial of ONS-5010 / LYTENAVA ™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD)
On track to submit new U.S. BLA for ONS-5010 in the first quarter of calendar 2022 and pre-commercial launch planning underway.
Commented Mr. C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics.
“... we possess positive, statistically significant results to support our plans to submit a BLA for ONS-5010 in the first calendar quarter of 2022.
.... is a tremendous amount of opportunity ahead for OTLK
...and the potential of ONS-5010, have continued to reinforce my confidence in our position as an up-and-coming leader in the retina space. We are dedicated to building momentum, shareholder value.
…. We are dedicated to building momentum, shareholder value, and ultimately potentially bringing the first FDA-approved ophthalmic formulation of bevacizumab to the retina community,”
Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference
Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, to participate in The Greatest Unmet Needs Facing Ophthalmology Today panel on Tuesday, August 17th at 9:00 AM ET
As part of the event, Mr. Trenary will participate in the panel, hosted by Matthew Caufield, Equity Research Analyst at H.C. Wainwright, The Greatest Unmet Needs Facing Ophthalmology Today. To register for the event.
https://ir.outlooktherapeutics.com/node/9581/pdf
Is Outlook Therapeutics (OTLK) Stock About To Start To Soar?
By Amsden Lindsay August 10, 2021, 10:01 AM (on InvestReader)
Outlook Therapeutics (NASDAQ: OTLK) stock has been running between $2 and $3 for most of this year. Last Tuesday, the company released a very important update, which pushed its stock to hit the $3 level again. So, is this stock about to start to soar?
Outlook Therapeutics is a biotech company that develops and commercializes various products for the healthcare market. ONS-5010 is the important one in its products, which is in Phase 3 clinical trial to treat retina diseases. The company reported positive efficacy and safety data from its Phase 3 NORSE TWO trial of ONS-5010. In NORSE TWO, ONS-5010 achieved statistically significant and clinically relevant primary and key secondary efficacy endpoints, and ONS-5010 was safe and well tolerated.
The company said that if ONS-5010 is successful, it will plan to submit for regulatory approval of ONS-5010 in multiple markets. Currently, there is currently no bevacizumab approved for ophthalmic indications in the United States. Globally, the nine major markets account for an estimated $13.1 billion market for anti-VEGF drugs to treat retina diseases. Anyway, that is the long-term potential of positive news surrounding this drug or trial. Therefore, OTLK stock is worth adding to your watchlist.
OTLK - Corporate Presentation - August 10, 2021
Very good news on Today OTLK Corporate Presentation
https://ir.outlooktherapeutics.com/static-files/046a3f66-c668-4bc3-a7c1-916236655b42
OTLK my view of what's happening to the OTLK price after Phase 3 excellent results:
a) Yesterday with the excellent news from OTLK Phase 3 results, Day Traders they bought in anticipation of high price rise
b) Institutional, as they had small positions (only 9.28% Yahoo Finance), went in the opposite direction with large volumes and doing short selling to avoid price increases and to be able to buy at bargain prices.
c) Price decline caused day trades need to close their open buy positions to minimize losses.
On OTLK Press Release August 3, 2021:
OTLK announced positive clinical and highly statistically significant top-line results, both the primary and key secondary endpoints in NORSE TWO with highly significant clinically relevant results, we have achieved the requirements agreed upon with the FDA.
The successful completion of this trial is the final step needed in our clinical evaluation of ONS-5010 to enable us to submit a Biologics License Application to the FDA.
I am long term investor on OTLK 1 or 2 Years and I believe in the huge potential of OTLK for BIG Profits. I AGREE Market is making a mistake!
I don't Sell I Keep Hold ALL of my OTLK shares.
$OTLK Chartmill "Outlook Therapeutics Inc is a setup today!"
Besides having an excellent technical rating, OTLK also presents a decent setup pattern. Prices have been consolidating lately. There is a very little resistance above the current price. We notice that large players showed an interest for OTLK in the last couple of days, which is a good sign.
The Chartmill team.
OTLK JULY 2021 Corporate Presentation
https://ir.outlooktherapeutics.com/static-files/fa0db660-47bc-4831-a8b4-0faa1a035833
OTLK - Today June 25, 2021 after market close OTLK will be add to Russel 2.000 Index.
This gem is ready to a new uptrend!
Outlook Therapeutics Announces Inclusion in the Russell 2000® Index effective June 25, 2021
https://ir.outlooktherapeutics.com/node/9521/pdf
ISELIN, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that as part of the annual reconstitution of the Russell stock indexes, Outlook Therapeutics has been selected to be added to the Russell 2000® Index effective June 25, 2021, after the close of the U.S. equity markets.
“We are very pleased to have been selected for inclusion in the Russell 2000® Index. Our placement in this widely used performance benchmark for small-cap companies reflects the hard work of the Outlook Therapeutics team and the value we have created over the past year. With our inclusion in the Russell 2000® we believe we are well-positioned to continue driving value with this increased market exposure,” said Lawrence A. Kenyon, President, CEO and CFO, Outlook Therapeutics.
The Russell 2000® Index measures the performance of the small-cap segment of the US equity market. The Russell 2000® Index is a subset of the Russell 3000® Index representing approximately 10% of the total market capitalization of that index. It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes which are part of FTSE Russell, a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide.
Thanks H2R
Hope Big Profits with OTLK for all of us!
Regards
pfelgueiras
New OTLK Corporate Presentation June 2021
https://ir.outlooktherapeutics.com/static-files/f1574845-1ba4-4b8d-bc1b-ecb7cb328b89
OTLK - Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3
Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial June 8, 2021
Topline readout of data from NORSE TWO (Phase 3-FDA) targeted for calendar Q3 2021
New Biologics License Application (BLA) filing anticipated in calendar Q1 2022
https://ir.outlooktherapeutics.com/node/9516/pdf
OTLK OUTLOOK THERAPEUTICS will be added to Russell 3000 in JUNE 2021
Good profits on the way!
See the list Russell 3000® Index – Additions in JUNE 2021
https://content.ftserussell.com/sites/default/files/russell_3000_index_additions_-_2021.pdf
OTLK OUTLOOK THERAPEUTICS is on RUSSEL 3.000
See the list Russell 3000® Index – Additions
https://content.ftserussell.com/sites/default/files/russell_3000_index_additions_-_2021.pdf
$OTLK I am very Bullish with good news on May 2021 Corporate Presentation.
https://ir.outlooktherapeutics.com/static-files/324c599d-e8a8-4152-b5ae-51e9eae016c5
$OTLK Three good news yesterday at $OTLK Virtual Clinical Day:
1) Everything is going well Phase 3 Results 3Q 2021 and BLA Submit 4Q 2021 and BLA approval on 1Q 2022
2) They already have a partnership for China (is one of the investors in OTLK)
3) When the OTLK ONS-5010 will be approved by the FDA, it is no longer allowed the market use the current compound currently uses.
I am Very Bullish with OTLK, my Price Target for 1Q 2022 is $25 (with BLA approval), if a Buyout happen will be above $50.
$OTLK President, CEO and CFO Lawrence A. Kenyon was featured in a video interview discussing the pivotal Phase 3 NORSE TWO trial and the potential for ONS-5010 ophthalmic bevacizumab to treat #wetAMD.
https://www.proactiveinvestors.com/companies/news/946333/outlook-therapeutics--almost-complete--with-pivotal-phase-3-norse-two-trial-to-treat-wet-amd-946333.html
Outlook Therapeutics is hoping to become the first and only company to commercialize an FDA-approved ophthalmic formulation of bevacizumab for use in wet AMD
https://www.proactiveinvestors.com/companies/news/947974/outlook-therapeutics-is-bringing-a-treatment-for-retinal-disease-to-the-market-at-the-right-time-947974.html
$OTLK Keep Buying and Holding for BIG PROFITS with the next 3 catalyst events:
1) Ongoing Phase 3 pivotal trial with topline data expected Q3 2021
2) Biologics License Application (BLA) submission on Q4 2021.
3) BLA FDA Approval in 1Q 2022.
After "Phase 3" topline data, OTLK "can have" a Buyout, I estimate it will be above $50,00 (see My View of Profits)
OTLK COMMERCIAL PLANNING ACTIVITIES UNDERWAY
With an enhanced safety and cost-effectiveness profile, Outlook Therapeutics expects ONS-5010 to be widely adopted by payors and clinicians worldwide and to become the first-line drug of choice for payor-mandated “step edit” in the United States for retinal indications:
1) Physician and Patient Outreach
2) Aligning Key Opinion Leaders
3) Payor Community Engagement